Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05954000 · ClinicalTrials.gov registry record · Phase 1
Reducing African-American CVD Disparities Intervention Optimization (RADIO) Individuals on Statins
A Phase 1 study of Medication Adherence, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT05954000 is a Phase 1 study of Medication Adherence that has completed, run by Northwell Health. The registered enrollment target is 9 participants, below the 1,657-participant average among 52 other Medication Adherence trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05954000, a Phase 1 study of Medication Adherence, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to identify the minimum effective dose (MED) of a multi-component behavioral change intervention required to increase levels of medication adherence among Black and African American individuals on primary prevention statin therapy who are at elevated risk for cardiovascular disease (CVD). The intervention will be comprised of 5 BCTs which have previously shown to be effective on increasing health behaviors: Goal Setting, Action Planning, Self-Monitoring, Feedback, and Prompts/Cues. Participants will complete a 2-week run-in period where medication adherence levels will be measured using a smart pill bottle and physical activity (PA) will be measured using Fitbit wearable devices. Then 42 participants will be randomized into 14 cohorts of 3 participants each for the intervention period. During the intervention period, participants will receive a multi-BCT intervention, the length of which varies between 1 and 10 weeks depending on the assigned dose. Assignment to doses will utilize a modified version of the Time-to-Event Continual Reassessment Method (TiTE-CRM) methodology to adjust the dose for each cohort based on the results from the previous cohort. After the intervention, there will be a 2-week follow-up period. The MED will be defined as the smallest BCT dose (defined by weeks of intervention) associated with 80% of participants having a 20% medication adherence increase between the run-in and the follow-up periods. The long-term goal is reduce incidence of CVD among Black and African American individuals by increasing adherence to primary prevention statin medications.
Conditions Studied
Interventions
- BEHAVIORAL 5 Behavioral Change Techniques
Study Locations (1)
New York
- Northwell Health - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2024-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05954000
The ClinicalTrials.gov registry entry for NCT05954000 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,657-participant average among 52 other Medication Adherence trials with a reported enrollment target (99% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Medication Adherence appearing as the primary indexed condition, and to 1 intervention - of which 5 Behavioral Change Techniques is the first listed.
NCT05954000 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05954000 about?
NCT05954000 is a clinical study titled "Reducing African-American CVD Disparities Intervention Optimization (RADIO) Individuals on Statins". The purpose of this project is to identify the minimum effective dose (MED) of a multi-component behavioral change intervention required to increase levels of medication adherence among Black and African American individuals on primary prevention statin therapy who are at elevated risk for cardiovas...
What is the current status of trial NCT05954000?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-08-01. Estimated completion is 2024-01-20.
What conditions does trial NCT05954000 study?
This clinical trial studies the following conditions: Medication Adherence.
What interventions are being tested in trial NCT05954000?
The interventions under investigation include: 5 Behavioral Change Techniques (BEHAVIORAL).
Who is sponsoring clinical trial NCT05954000?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05954000 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medication Adherence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A BCT Intervention for Medication Adherence Among Individuals on Statins
COMPLETED · Phase 1
-
Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults
COMPLETED · Phase 1
-
Nurse Delivered Cell Phone Adherence Intervention (Pick It UP)
COMPLETED · Phase 1
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Medication Adherence Program
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.